Browse articles from EyeWorld.org on the topic of the cornea. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Astigmatism, whether regular or irregular, is something that many ophthalmologists are familiar with. Three experts delved into the issue and how to deal with it, particularly highlighting the pinhole pupilloplasty technique.
➤ Phase 1/2 trial update for Leber congenital amaurosis gene therapy in pediatric patients ➤ Primary endpoint not met in Phase 2b trial investigating persistent corneal epithelial defect treatment ➤ Study: treatment for uveal melanoma could improve survival rate ➤ Company news ➤ ASCRS news and events
Cornea Editor Julie Schallhorn, MD, shared the story of a personal friend of hers to introduce the “must-read” article on corneal side effects of cancer-specific therapies, also mentioning the articles on Sjogren’s disease and pinhole apertures in the management of irregular corneas.
The president and CEO of the Sjögren’s Foundation as well as two ophthalmologists spoke about the diagnosis journey, available treatments, and future hopes for patients with Sjögren’s disease.
➤ Priority review granted to possible LHON treatment ➤ Update on drug in development for neuropathic corneal pain ➤ FDA approves generic bimatoprost ➤ Phase 1/2a clinical results for first-in-human retinal pigment epithelial stem cell therapy ➤ Adult dosing complete in trial for X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events
Antibody drug conjugates, an emerging area in cancer therapy, can pose a risk to the eye and cause adverse ocular events. Several experts discussed the research, what they’ve seen in terms of side effects, and considerations for patients taking these drugs and the eyecare providers monitoring them.
➤ Updates on trial and patient experience with artificial cornea ➤ Positive clinical trial update for Usher syndrome type 1B ➤ Positive topline data from Phase 2 study investigating DME and nAMD treatment ➤ First patient dosed in second Phase 3 trial evaluating drop for night vision disturbances ➤ Partnership and company news ➤ ASCRS news and events
➤ Accommodating lens implanted in first patient ➤ First patient dosed in Phase 2 trial investigating treatment for normal tension glaucoma ➤ Primary endpoint met in Phase 3 trial for glaucoma drop ➤ CE mark approvals ➤ Regenerative Medicine Advanced Therapy designation granted to investigational gene therapy for Stargardt disease ➤ ASCRS news and events
➤ Topline Phase 2 results for drug treating neuropathic corneal pain ➤ Phase 3 blepharitis treatment doesn’t meet primary endpoint ➤ Study: therapeutic potential of collagen mimetic peptides for myopia ➤ FDA accepts NDA resubmission for dry eye therapy ➤ Partnership news ➤ ASCRS news and events
Results from the Zoster Eye Disease Study (ZEDS) were first presented last year. This randomized clinical trial looked at the use of low dose valacyclovir for reducing complications with herpes zoster ophthalmicus. Two cornea specialists spoke to EyeWorld about the results, highlighting recently published papers on findings from the study.